Table 3.
Association between mSASSS and atherosclerotic plaques adjusting for age, smoking status, CRP, NSAIDs intake and disease duration.
| Crude model | Adjusted for age and smoking | Adjusted for age, smoking and elevated CRP* | Adjusted for age, smoking, elevated CRP* and NSAIDs intake | Adjusted for disease duration, smoking, elevated CRP* and NSAIDs intake | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
| Total mSASSS | 1.07 (1.04–1.11) | <0.001 | 1.04 (1.01–1.08) | 0.019 | 1.05 (0.99–1.11) | 0.076 | 1.05 (0.99–1.12) | 0.096 | 1.05 (1.01–1.12) | 0.034 |
| Cervical mSASSS | 1.13 (1.07–1.20) | <0.001 | 1.08 (1.02–1.56) | 0.019 | 1.07 (0.98–1.17) | 0.128 | 1.06 (0.98–1.16) | 0.155 | 1.09 (1.00–1.19) | 0.042 |
| Lumbar mSASSS | 1.11 (1.06–1.18) | <0.001 | 1.07 (1.01–1.14) | 0.036 | 1.09 (1.00–1.21) | 0.062 | 1.09 (0.99–1.22) | 0.070 | 1.10 (1.01–1.22) | 0.037 |
*
Elevated CRP at more than 50% of the time-points during 5 years.
CI, confidence interval; CRP, C-reactive protein; mSASSS, modified Stoke ankylosing spondylitis spinal score; NSAIDs, non-steroidal anti-inflammatory drugs.